Literature DB >> 35132180

Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion.

Marco Trerotola1,2, Saverio Alberti3,4, Emanuela Guerra5,6, Valeria Relli5, Martina Ceci5, Romina Tripaldi5, Pasquale Simeone5,7,8, Anna Laura Aloisi5, Ludovica Pantalone5, Rossana La Sorda5, Rossano Lattanzio5,9, Andrea Sacchetti5,10, Kristina Havas5,11, Simone Guarnieri12,13, Daniele Vergara14, Isabelle Fournier15, Michel Salzet15, Nicola Tinari6, Mauro Piantelli5,6.   

Abstract

Trop-2 is a transmembrane signal transducer that is overexpressed in most human cancers, and drives malignant progression. To gain knowledge on the higher-order molecular mechanisms that drive Trop-2 signaling, we applied next-generation sequencing, proteomics, and high-resolution microscopy to models and primary cases of human colorectal cancer (CRC). We had previously shown that Trop-2 induces a Ca2+ signal. We reveal here that Trop-2 binds the cell membrane Na+/K+-ATPase, and that clustering of Trop-2 induces an intracellular Ca2+ rise followed by membrane translocation of PKCα, which in turn phosphorylates the Trop-2 cytoplasmic tail. This feed-forward signaling is promoted by the binding of Trop-2 to the PKCα membrane-anchor CD9. CRISPR-based inactivation of CD9 in CRC cells shows that CD9 is required by Trop-2 for recruiting PKCα and cofilin-1 to the cell membrane. This induces malignant progression through proteolytic cleavage of E-cadherin, remodeling of the β-actin cytoskeleton, and activation of Akt and ERK. The interaction between Trop-2 and CD9 was validated in vivo in murine models of CRC growth and invasion. Overexpression of the components of this Trop-2-driven super-complex significantly worsened disease-free and overall survival of CRC patients, supporting a pivotal relevance in CRC malignant progression. Our findings demonstrate a previously unsuspected layer of cancer growth regulation, which is dormant in normal tissues, and is activated by Trop-2 in cancer cells.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35132180     DOI: 10.1038/s41388-022-02220-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  57 in total

1.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

Authors:  Thorsten Maretzky; Karina Reiss; Andreas Ludwig; Julian Buchholz; Felix Scholz; Erhardt Proksch; Bart de Strooper; Dieter Hartmann; Paul Saftig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

Review 2.  Targeting Topoisomerase I in the Era of Precision Medicine.

Authors:  Anish Thomas; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis.

Authors:  Marco Trerotola; Jing Li; Saverio Alberti; Lucia R Languino
Journal:  J Cell Physiol       Date:  2012-11       Impact factor: 6.384

4.  Upregulation of Trop-2 quantitatively stimulates human cancer growth.

Authors:  M Trerotola; P Cantanelli; E Guerra; R Tripaldi; A L Aloisi; V Bonasera; R Lattanzio; R de Lange; U H Weidle; M Piantelli; S Alberti
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

5.  A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer.

Authors:  Emanuela Guerra; Marco Trerotola; Roberta Dell' Arciprete; Veronica Bonasera; Barbara Palombo; Tarek El-Sewedy; Tommaso Ciccimarra; Carlo Crescenzi; Franco Lorenzini; Cosmo Rossi; Giovanna Vacca; Rossano Lattanzio; Mauro Piantelli; Saverio Alberti
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Human Trop-2 is a tumor-associated calcium signal transducer.

Authors:  E Ripani; A Sacchetti; D Corda; S Alberti
Journal:  Int J Cancer       Date:  1998-05-29       Impact factor: 7.396

7.  Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors.

Authors:  Emanuela Guerra; Marco Trerotola; Romina Tripaldi; Anna Laura Aloisi; Pasquale Simeone; Andrea Sacchetti; Valeria Relli; Antonella D'Amore; Rossana La Sorda; Rossano Lattanzio; Mauro Piantelli; Saverio Alberti
Journal:  Clin Cancer Res       Date:  2016-03-28       Impact factor: 12.531

8.  The Trop-2 signalling network in cancer growth.

Authors:  E Guerra; M Trerotola; A L Aloisi; R Tripaldi; G Vacca; R La Sorda; R Lattanzio; M Piantelli; S Alberti
Journal:  Oncogene       Date:  2012-05-07       Impact factor: 9.867

9.  Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.

Authors:  Marco Trerotola; Emanuela Guerra; Zeeshan Ali; Anna Laura Aloisi; Martina Ceci; Pasquale Simeone; Angela Acciarito; Paola Zanna; Giovanna Vacca; Antonella D'Amore; Khouloud Boujnah; Valeria Garbo; Antonino Moschella; Rossano Lattanzio; Saverio Alberti
Journal:  Neoplasia       Date:  2021-04-08       Impact factor: 5.715

10.  Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.

Authors:  Emanuela Guerra; Marco Trerotola; Valeria Relli; Rossano Lattanzio; Romina Tripaldi; Giovanna Vacca; Martina Ceci; Khouloud Boujnah; Valeria Garbo; Antonino Moschella; Romina Zappacosta; Pasquale Simeone; Robert de Lange; Ulrich H Weidle; Maria Teresa Rotelli; Arcangelo Picciariello; Raffaella Depalo; Patrizia Querzoli; Massimo Pedriali; Enzo Bianchini; Domenico Angelucci; Giuseppe Pizzicannella; Carla Di Loreto; Mauro Piantelli; Laura Antolini; Xiao-Feng Sun; Donato F Altomare; Saverio Alberti
Journal:  Neoplasia       Date:  2021-07-25       Impact factor: 5.715

View more
  2 in total

1.  ATF2 loss promotes tumor invasion in colorectal cancer cells via upregulation of cancer driver TROP2.

Authors:  Kerstin Huebner; Katharina Erlenbach-Wuensch; Jan Prochazka; Ilir Sheraj; Chuanpit Hampel; Blanka Mrazkova; Tereza Michalcikova; Jolana Tureckova; Veronika Iatsiuk; Anne Weissmann; Fulvia Ferrazzi; Philipp Kunze; Enise Nalli; Elisabeth Sammer; Annemarie Gehring; Marie M Cheema; Markus Eckstein; Eva-Maria Paap; Agnes Soederberg; Corinna Fischer; Sushmita Paul; Vijayalakshmi Mahadevan; Benardina Ndreshkjana; Melanie A Meier; Susanne Muehlich; Carol I Geppert; Susanne Merkel; Robert Grutzmann; Adriana Roehe; Sreeparna Banerjee; Arndt Hartmann; Radislav Sedlacek; Regine Schneider-Stock
Journal:  Cell Mol Life Sci       Date:  2022-07-15       Impact factor: 9.207

2.  TROP2 Represents a Negative Prognostic Factor in Colorectal Adenocarcinoma and Its Expression Is Associated with Features of Epithelial-Mesenchymal Transition and Invasiveness.

Authors:  Jiří Švec; Monika Šťastná; Lucie Janečková; Dušan Hrčkulák; Martina Vojtěchová; Jakub Onhajzer; Vítězslav Kříž; Kateřina Galušková; Eva Šloncová; Jan Kubovčiak; Lucie Pfeiferová; Jan Hrudka; Radoslav Matěj; Petr Waldauf; Lukáš Havlůj; Michal Kolář; Vladimír Kořínek
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.